The abstract reports on high implant survival rate and good clinical outcome for 22 patients who were treated with Episurf Medical's personalised implant Episealer® Knee as treatment for chondral and osteochondral defects in the knee during 2013 - 2023, at AZ Monica Hospital, Antwerp, Belgium.

"We appreciate the continued interest in the clinical outcome for patients treated with our Episealer® Knee implants. This congress has a focus on the large orthopaedic segment of unicompartmental and patellofemoral replacements for osteoarthritis. The acceptance of this abstract for presentation further confirms that surgeons traditionally more focused on prosthesis surgery, now also show an interest in our less invasive, joint-preserving treatment alternative. We believe we are leading the development globally of smaller implants, hence we are excited about this presentation. Further, this is the first presentation of clinical data where Episealer® patients treated 10 years ago are included. The aim is, of course, to start talking about long-term data for the Episealer®, which is some kind of ultimate goal. This is an important step on the way," says Pål Ryfors, CEO Episurf Medical.